Irish patients are being denied access to nine drugs that are widely available across Europe, largely on cost grounds. A new bulletin published by the Irish Pharmaceutical Healthcare Association (IPHA) has found that nine medicines currently in the Irish reimbursement system are already available in 12 other western European countries on average.
Cancer and cardiovascular care are the main areas where Ireland is lagging behind, according to the IPHA. This initial report says that seven new therapies have been approved by the State so far this year.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.